Array Biopharma (ARRY) Reports Updated Results for Phase 3 BEACON CRC Trial Evaluating Triplet Combination of Encorafenib, Binimetinib and Cetuximab at ASCO 2018
Tweet Send to a Friend
Array BioPharma Inc. (NASDAQ: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
